Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mazdutide - Eli Lilly and Company

Next Previous
Drug Profile

Mazdutide - Eli Lilly and Company

Alternative Names: IBI-362; LY-3305677; OXM-3; Xinermei

Latest Information Update: 21 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Innovent Biologics
  • Class Antihyperglycaemics; Antihypertensives; Gastrointestinal hormones; Heart failure therapies; Hepatoprotectants; Obesity therapies; Peptides; Sleep disorder therapies; Uricosurics
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity
  • Registered Type 2 diabetes mellitus
  • Phase III Hypertension; Non-alcoholic fatty liver disease; Sleep apnoea syndrome
  • Phase II Alcoholism; Heart failure; Non-alcoholic steatohepatitis
  • Phase I/II Polycystic ovary syndrome
  • Preclinical Hyperuricaemia

Most Recent Events

  • 08 Jun 2026 Pharmacokinetics data from a phase I trial in Obesity presented at the 86th Annual Scientific Sessions of the American Diabetes Association (ADA-2026)
  • 08 Jun 2026 Pharmacodynamics data from the phase III GLORY-2 trial in Obesity presented at the 86th Annual Scientific Sessions of the American Diabetes Association (ADA-2026)
  • 08 Jun 2026 Updated adverse events data from the phase III DREAMS-3 trial in Obesity and Type II diabetes mellitus presented at the 86th Annual Scientific Sessions of the American Diabetes Association (ADA-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top